Printer Friendly

Browse Atezolizumab topic

Articles

1-205 out of 205 article(s)
Title Author Type Date Words
I-MAB announces presentation on uliledlimab at ASCO 2021 meeting. Apr 14, 2021 209
OncoCyte presents new data on potential for pan-cancer utility of DetermaIO. Apr 11, 2021 284
Roche's Tecentriq receives positive CHMP opinion as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer. Mar 29, 2021 252
Roche's Tecentriq receives positive CHMP opinion as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer. Mar 29, 2021 251
I-Mab Touts Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the US. Feb 8, 2021 453
Clinical characteristics and outcomes for young patients with advanced urothelial carcinoma. Chehroudi, All Cyrus; Lavoie, Jean-Michel; Black, Peter C.; Eigl, Bernhard J. Report Feb 1, 2021 2356
Japan's Drug Regulation Framework: Aiming for Better Health or Bigger Profits? Ozaki, Akihiko; Senoo, Yuki; Saito, Hiroaki; Crump, Andy; Tanimoto, Tetsuya Jan 1, 2021 1283
Roche Secures European Approval For Tecentriq As Liver Cancer Drug. Nov 2, 2020 192
Corvus Pharmaceuticals reports Q3 EPS (33c), consensus (24c). Financial report Oct 29, 2020 285
Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo. Oct 26, 2020 185
NeoImmuneTech Forges a Second Clinical Collaboration with Roche to Evaluate NT-I7 (efineptakin alfa) in Combination with PD-L1 Checkpoint Inhibitor in First-line Non-small Cell Lung Cancer. Oct 22, 2020 318
Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of Oral Tyrosine Kinase Inhibitor. Oct 12, 2020 484
Exelixis announces new XL092 data at ENA Symposium. Oct 9, 2020 344
FDA approves triple-drug combination for melanoma. Mulcahy, Nick Oct 1, 2020 248
Exelixis announces results from two cohorts of COSMIC-021 trial. Financial report Sep 21, 2020 213
Pieris presents data from monotherapy, atezolizumab combo studies of PRS-343. Sep 20, 2020 537
Cancer patient first to receive new treatment. ANNA TWIZELL anna.twizell@reachplc.com @annatwizell Sep 18, 2020 470
The Current Strategies for Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer: The Place of Immunotherapy in Future. Ercelep, Ozlem Sep 1, 2020 2358
Development of an Immune-Related Risk Signature in Patients with Bladder Urothelial Carcinoma. Jiang, Yaofei; Wang, Yibing; Li, Cong; Zou, Zhenhong; Liang, Bo Report Aug 31, 2020 4859
KAHR wins FDA clearance to initiate Phase I/II clinical trial of DSP107 for treating solid tumors. Aug 13, 2020 216
KAHR wins FDA clearance to initiate Phase I/II clinical trial of DSP107 for treating solid tumors. Aug 13, 2020 212
FDA Approves Genentech's Tecentriq plus Cotellic and Zelboraf for People with Advanced Melanoma. Aug 3, 2020 749
Shorts. Klotter, Jule Aug 1, 2020 1918
Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis. Liu, Haoran; Ye, Tao; Yang, Xiaoqi; Lv, Peng; Wu, Xiaoliang; Zhou, Hui; Lu, Hongyan; Tang, Kun; Ye, Jul 31, 2020 14681
Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer. Inoue, Akira Jul 1, 2020 4156
Molecular Targeted Cancer Therapies and the Kidney. Aksu, Ozge Bas; Sadioglu, Rezzan Eren; Sengul, Sule Jul 1, 2020 6275
The expanding role of biomarker testing in non-small cell lung cancer. Vennapusa, Bharathi Jul 1, 2020 1948
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment. Roviello, Giandomenico; Casadei-Gardini, Andrea; Nobili, Stefania; Mini, Enrico; Fancelli, Sara Jun 30, 2020 2525
Identification of PDLl-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors. Wu, Yanping; Lin, Lianjun; Liu, Xinmin Jun 30, 2020 5697
Profiles of Immune Infiltration and Prognostic Immunoscore in Lung Adenocarcinoma. Li, Yanyan; Tao, Liping; Cai, Weiyang Jun 30, 2020 9865
Promising signs in trials for personalised cancer vaccines. Jun 23, 2020 199
Roche's Tecentriq in combination with Avastin gains FDA approval for most common liver cancer. Jun 3, 2020 225
Roche's Tecentriq in combination with Avastin gains FDA approval for most common liver cancer. Jun 3, 2020 229
Roche's Tecentriq Approved In US For Most Common Form Of Liver Cancer. Jun 2, 2020 346
LONDON BRIEFING: Tesco's Finance Boss Alan Stewart To Retire. Jun 2, 2020 1674
GLOBAL TOP NEWS SUMMARY: European Stocks Shrug Off US Unrest. Jun 2, 2020 1824
The Cancer Immunotherapy Biomarker Testing Landscape. Walk, Eric E.; Yohe, Sophia L.; Beckman, Amy; Schade, Andrew; Zutter, Mary M.; Pfeifer, John; Berry, Jun 1, 2020 16518
An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient. Krukowska, Kinga; Kieszko, Robert; Kurek, Katarzyna; Chmielewska, Izabela; Krawczyk, Pawel; Milanows May 31, 2020 2517
Pulmonary Complications Secondary to Immune Checkpoint Inhibitors. Ahmad Hasan Albitar, Hasan; Duma, Narjust; Leventakos, Konstantinos; De Moraes, Alice Gallo May 31, 2020 3226
The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. Nie, Run-Cong; Zhao, Chong-Bang; Xia, Xiao-Wei; Luo, Ying-Shan; Wu, Ting; Zhou, Zhi-Wei; Yuan, Shu-Q Report May 31, 2020 6865
Gossamer Bio announces presentation of KEYNOTE-A36 Phase 1/2 study data at ASCO. May 29, 2020 276
Deep and Prolonged Response to Aurora A Kinase Inhibitor and Subsequently to Nivolumab in MYCL1-Driven Small-Cell Lung Cancer: Case Report and Literature Review. Kolla, Bhaskar C.; Racila, Emilian; Patel, Manish R. Apr 30, 2020 3663
Metastatic Small-Cell Lung Cancer Presenting as Primary Adrenal Insufficiency. Esperti, Shawn; Stoelting, Austen; Scibelli, Nicolina; Moccia, David; Patel, Dveet; Haughton, Michae Mar 31, 2020 2035
Advanced Lung Adenocarcinoma Patient with ERBB2 Amplification Identified by Comprehensive Genomic Profiling Benefits from Trastuzumab. Tao, Chi-Wei; Chen, Mei-Yin; Tseng, Ching-Min; Lapke, Nina; Chen, Shu-Jen; Tan, Kien Thiam Report Mar 31, 2020 2823
Synlogic provides business, clinical update amid COVID-19 pandemic. Mar 30, 2020 412
Identification of Prognostic Immune Genes in Bladder Urothelial Carcinoma. Su, Qisheng; Sun, Yan; Zhang, Zunni; Yang, Zheng; Qiu, Yuling; Li, Xiaohong; Mo, Wuning Mar 1, 2020 4600
FDA Grants Priority Review to Genentech's Tecentriq Monotherapy as First-line Treatment of Certain People with Advanced Non-small Cell Lung Cancer. Feb 24, 2020 527
FDA Grants Priority Review to Genentech's Tecentriq Monotherapy as First-line Treatment of Certain People with Advanced Non-small Cell Lung Cancer. Feb 20, 2020 527
Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database. Oake, Justin D.; Patel, Premal; Lavallee, Luke T.; Lattouf, Jean-Baptiste; Saarela, Olli; Klotz, Lau Feb 1, 2020 4689
Genentech's Phase III Study of Tecentriq in People with Muscle-invasive Urothelial Cancer Fails to Meet Primary Endpoint. Jan 27, 2020 410
Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer. Jan 24, 2020 1191
European Commission approves Roche's Polivy for people with previously treated aggressive lymphoma. Jan 21, 2020 1589
AI Therapeutics Creates AI-Driven Drug Development Platform. Jan 21, 2020 366
Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study. Li, Yu-Chen; Zhou, Quan; Song, Qing-Kun; Wang, Rui-Bin; Lyu, Shuzhen; Guan, Xiudong; Zhao, Yan-Jie; Report Jan 1, 2020 4948
Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. Cembrola, Biancamaria; Ruzza, Valentino; Troise, Fulvia; Esposito, Maria Luisa; Sasso, Emanuele; Caf Jan 1, 2020 15860
Safety and Efficacy in Relapsed or Refractory Classic Hodgkin's Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials. Zhang, Xueyan; Chen, Li; Zhao, Yawei; Yin, Huiru; Ma, He; He, Miao Dec 31, 2019 9556
Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients. Imoto, Koji; Kohjima, Motoyuki; Hioki, Tomonobu; Kurashige, Tomoyuki; Kurokawa, Miho; Tashiro, Shige Dec 31, 2019 7227
Overweight, Obese People More Likely To Survive Cancer. Darwin Malicdem Dec 31, 2019 380
An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors. Baseri, Babak; Samra, Bachar; Tam, Eric; Chiu, Edwin; Leaf, Andrea Dec 31, 2019 4860
Skeletal Muscle Metastasis to Vastus Lateralis from a Urothelial Carcinoma: A Case Report and Review of Its Diagnosis and Management. Mainwaring, A.M.; Wells, H.; Banks, T.; Ellul, T.; Bose, P. Dec 31, 2019 2832
Obesity May Boost Effectiveness of a Lung Cancer Therapy. Dec 30, 2019 490
Study suggests high BMI may improve cancer survival. ANI Report Dec 29, 2019 477
Cancer drug better for fatter patients; Scientists term it 'obesity paradox'. LUCY THORNTON Dec 27, 2019 115
BMI, Survival Linked in NSCLC Treated With Atezolizumab; Overall, progression-free survival improved for patients with high BMI; link strongest with high PD-L1 expression. Dec 27, 2019 268
Exelixis signs collaboration agreement with Roche. Dec 23, 2019 148
Exelixis signs collaboration agreement with Roche. Dec 23, 2019 144
Genentech meets primary endpoint in Phase III IMspire150 study of BRAF V600 mutation-positive advanced melanoma. Dec 17, 2019 164
Genentech meets primary endpoint in Phase III IMspire150 study of BRAF V600 mutation-positive advanced melanoma. Dec 17, 2019 160
Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma. Dec 13, 2019 1275
Global Monoclonal Antibodies (MAbS) Market Report 2020 with Profiles of Johnson & Johnson, Merck, AbbVie, Amgen, Glaxosmithkline. Report Dec 11, 2019 982
First Patient Dosed with Third ImmTAC Bispecific. Dec 9, 2019 226
FDA approves Roche's Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer. Dec 4, 2019 1548
What the Oncologist Needs From the Pathologist for Immune Therapies. Bernicker, Eric H. Dec 1, 2019 3001
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. Carbone, Carmine; Piro, Geny; Noia, Vincenzo Di; D'Argento, Ettore; Vita, Emanuele; Ferrara, Miriam Nov 30, 2019 6998
Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages. Lu, Di; Ni, Zhen; Liu, Xiguang; Feng, Siyang; Dong, Xiaoying; Shi, Xiaoshun; Zhai, Jianxue; Mai, Shi Nov 30, 2019 5370
The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature. Tsiouprou, Ioanna; Zaharias, Athanasios; Spyratos, Dionisios Nov 30, 2019 5174
Roche reports positive results from phase three Tecentriq trial in combination with Avastin. Nov 26, 2019 162
Roche reports positive results from phase three Tecentriq trial in combination with Avastin. Nov 26, 2019 158
Henaelwths. Nov 17, 2019 381
CHMP recommends conditional EU approval of Roche's Polivy for people with previously treated aggressive lymphoma. Nov 15, 2019 1494
Breast and kidney cancer drugs get approval for use across Scotland's NHS. Nov 11, 2019 373
Global Neuroendocrine Tumors (NETs) Market Insights, Epidemiology and Market Forecasts, 2017-2018 & 2019-2028. Nov 7, 2019 1126
Exelixis reports Q3 adjusted EPS 34c, consensus 19c. Financial report Oct 30, 2019 107
Seattle Genetics (NASDAQ: SGEN). Oct 30, 2019 1843
Global Small Cell Lung Cancer Pipeline Report 2019: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease. Report Oct 29, 2019 864
FDA Labeling Restriction Quickly Reflected in Oncology Practice; FDA label change linked to decrease in immunotherapy use, increases in chemotherapy use, PD-L1 testing. Oct 29, 2019 327
Chugai Pharmaceutical Co., Ltd. - Tecentriq in Combination with Avastin Increases Overall Survival and Progression-free Survival as an Initial Treatment in People with Unresectable Hepatocellular Carcinoma -- 21/10/2019. Oct 22, 2019 241
Bavarian Nordic provides update on stage 1 of phase 2 study of CV301 in bladder cancer. Oct 21, 2019 353
Roche's Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma. Oct 21, 2019 1465
Bavarian Nordic provides update on stage 1 of phase 2 study of CV301 in bladder cancer. Oct 21, 2019 354
Bavarian Nordic provides update on stage 1 of phase 2 study of CV301 in bladder cancer. Oct 21, 2019 349
Seattle Genetics (NASDAQ: SGEN). Oct 17, 2019 1994
Seattle Genetics (NASDAQ: SGEN). Oct 9, 2019 1805
China's drug watchdog grants approval to I-Mab Biopharma's IND application for TJD5. Oct 7, 2019 250
China's drug watchdog grants approval to I-Mab Biopharma's IND application for TJD5. Oct 7, 2019 246
NHS denied use of cancer drug; UK & WORLD. Oct 3, 2019 147
NHS denied use of cancer drug; UK & WORLD. Oct 3, 2019 147
Roche Products UK - Roche presents positive Phase III results for Tecentriq[R] (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer -- 30/9/2019. Oct 2, 2019 419
Seattle Genetics (NASDAQ: SGEN). Oct 2, 2019 1843
Genentech (SIX: RO, ROG; OTCQX: RHHBY) - Genentech Presents Positive Phase III Results for Tecentriq (Atezolizumab) in Combination With Platinum-Based Chemotherapy in People With Previously Untreated Advanced Bladder Cancer -- 30/9/2019. Oct 1, 2019 579
BeyondSpring presents trial design for DUBLIN-3 study BPI-2358-103. Oct 1, 2019 344
Lichenoid dermatitis with checkpoint inhibitor use described. Nogrady, Bianca Oct 1, 2019 472
Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. Duffy, Michael J.; Crown, John Oct 1, 2019 8376
Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer. Sep 30, 2019 1469
Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors. Schepisi, Giuseppe; Brighi, Nicole; Cursano, Maria Concetta; Gurioli, Giorgia; Ravaglia, Giorgia; Al Sep 30, 2019 8889
Invasive Aspergillosis in a Patient with Stage III (or 3a or 3b) Non-Small-Cell Lung Cancer Treated with Durvalumab. Gupta, Ashish; Tun, Aung; Ticona, Katy; Baqui, Aam; Guevara, Elizabeth Sep 30, 2019 2150
Immunomedics presents interim data from TROPHY-U-01 open-label Phase 2 trial. Sep 29, 2019 296
Roche's Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma. Sep 27, 2019 1919
Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer. Sep 27, 2019 1411
Seattle Genetics (NASDAQ: SGEN). Sep 25, 2019 1844
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress. Sep 23, 2019 1237
Seattle Genetics (NASDAQ: SGEN). Sep 19, 2019 1806
Roche's Tecentriq improves overall survival rate in IMpower110 study. Sep 13, 2019 201
Roche's Tecentriq improves overall survival rate in IMpower110 study. Sep 13, 2019 197
Roche's Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy. Sep 12, 2019 1277
Roche (Philippines) Inc. Immunotherapy treatment available for advanced Metastatic Bladder Cancer. Sep 6, 2019 751
European Commission approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer. Sep 6, 2019 1496
European Commission approves Roche's new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer. Sep 6, 2019 333
Roche Gets Thumbs Up In Europe To Expand Lung Cancer Drug. Sep 6, 2019 163
Global Immune Checkpoint Inhibitors Market Report, 2019-2022 - Opdivo & Keytruda Presents Significant Growth Opportunity. Report Sep 5, 2019 826
What the Oncologist Needs From the Pathologist for Tyrosine Kinase Inhibitor Therapies. Bernicker, Eric H. Sep 1, 2019 3752
Seattle Genetics (NASDAQ: SGEN). Aug 29, 2019 1805
European Commission approves Roche's Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer. Aug 29, 2019 366
Roche launches VENTANA PD-L1 (SP142) Assay in CE markets as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq. Aug 29, 2019 1290
Chugai Pharmaceutical Co., Ltd. - Tecentriq, an Anti-PD-L1 Antibody, Receives Approval for Additional Indication of Extensive-Stage Small Cell Lung Cancer -- 22/8/2019. Aug 27, 2019 727
Non-Small Cell Lung Cancer Market Huge Growth Opportunities and Challenges to Watch in 2019. Aug 22, 2019 950
Seattle Genetics (NASDAQ: SGEN). Aug 20, 2019 1806
Seattle Genetics (NASDAQ: SGEN). Aug 13, 2019 1806
Genentech (SIX: RO, ROG; OTCQX: RHHBY) - Genentech's Tecentriq[R] (Atezolizumab) Plus Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Advanced Bladder Cancer -- 4/8/2019. Aug 13, 2019 456
Genentech's Tecentriq Plus Platinum-based Chemotherapy Reduced the Risk of Disease Worsening or Death in People with Previously Untreated Advanced Bladder Cancer. Aug 6, 2019 577
Genentech (SIX: RO, ROG; OTCQX: RHHBY) - Genentech's Tecentriq[R] (Atezolizumab) Plus Platinum-Based Chemotherapy Reduced the Risk of Disease Worsening or Death in People With Previously Untreated Advanced Bladder Cancer -- 4/8/2019. Aug 6, 2019 456
Roche's Tecentriq plus platinum-based chemotherapy reduced the risk of disease worsening or death in people with previously untreated advanced bladder cancer. Aug 5, 2019 1208
Foundation Medicine Names Priti Hegde, Ph.D., as Chief Scientific Officer; Renowned oncology leader to head scientific innovation at Foundation Medicine. Aug 5, 2019 561
Genentech says Phase III IMvigor130 study met co-primary endpoint. Aug 5, 2019 201
Seattle Genetics (NASDAQ: SGEN). Jul 31, 2019 1808
Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer. Bari, Shahla; Muzaffar, Jameel; Chan, Austin; Jain, Sanjay R.; Haider, Ahmad M.; Curry, Marjorie Ada Jul 31, 2019 3346
DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. Gilmore, Elaine; McCabe, Nuala; Kennedy, Richard D.; Parkes, Eileen E. Jul 31, 2019 10417
European Medicines Agency committee grants positive opinion to Roche's Tecentriq (atezolizumab) and chemotherapy combination. Jul 30, 2019 184
European Medicines Agency committee grants positive opinion to Roche's Tecentriq (atezolizumab) and chemotherapy combination. Jul 30, 2019 180
CHMP recommends EU approval of Roche's Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer. Jul 26, 2019 1395
Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer. Jul 26, 2019 268
Celgene Corporation (NASDAQ: CELG). Jul 25, 2019 1875
Seattle Genetics (NASDAQ: SGEN). Jul 25, 2019 1844
Celgene Corporation (NASDAQ: CELG). Jul 17, 2019 1925
Seattle Genetics (NASDAQ: SGEN). Jul 17, 2019 1844
Exelixis Updates Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors. Jul 16, 2019 1007
Exelixis expands COSMIC-021 study, adds four new cohorts. Jul 15, 2019 634
Celgene Corporation (NASDAQ: CELG). Jul 9, 2019 1875
Celgene Corporation (NASDAQ: CELG). Jul 4, 2019 1924
European Medicines Agency's Committee for Medicinal Products for Human Use recommends approval of Roche's Tecentriq plus Abraxane. Jul 2, 2019 156
European Medicines Agency's Committee for Medicinal Products for Human Use recommends approval of Roche's Tecentriq plus Abraxane. Jul 2, 2019 152
SHOW CLINICAL SPOTLIGHTS. Jul 1, 2019 1155
Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC). Sheng, Iris Y.; Kruse, Megan; Leininger, Kathryn M.; Ornstein, Moshe C. Report Jun 30, 2019 882
Celgene Corporation (NASDAQ: CELG). Jun 25, 2019 1921
Celgene Corporation (NASDAQ: CELG). Jun 18, 2019 1924
Celgene Corporation (NASDAQ: CELG). Jun 13, 2019 1881
Ipsen - New investigational clinical data for Ipsen's oncology products in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting - 24/5/2019. Jun 13, 2019 342
Ipsen - New investigational clinical data for Ipsen's oncology products in 11 solid tumor types to be presented at 2019 ASCO Annual Meeting - 24/5/2019. Jun 5, 2019 341
The Prevalence of Systemic Rheumatic Diseases Among Breast Cancer Patients and Its Relationship With Survival. Sunar, Veli; Ates, Ozturk; Aslan, Alma Korcali; Karakas, Yusuf; Altundag, Mustafa Kadri Jun 1, 2019 3961
Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma. Zajac, Magdalena; Boothman, Anne-Marie; Ben, Yong; Gupta, Ashok; Jin, Xiaoping; Mistry, Amita; Sabal Jun 1, 2019 8492
The ADC Market is Fast Evolving: Applications of ADCs are widening and improvements in the manufacturing process meet industry requirements. Johnson, Charlie Jun 1, 2019 1867
Immunotherapy in Prostate Cancer. Bolat, Deniz; Haydaroglu, Ayfer Jun 1, 2019 4730
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naive Vision of a Single Biomarker. Signorelli, Diego; Giannatempo, Patrizia; Grazia, Giulia; Aiello, Marco Maria; Bertolini, Federica; May 31, 2019 11914
Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis. Zhang, Leyin; Sun, Leitao; Yu, Jieru; Shan, Feiyu; Zhang, Kai; Pang, Xi; Ma, Chenghao; Zhang, Yinan; May 31, 2019 9612
Celgene Corporation (NASDAQ: CELG). May 29, 2019 1881
Seattle Genetics Appoints Taylor as Chief Commercial Officer. May 24, 2019 383
Synlogic Forges Clinical Collaboration to Evaluate SYNB1891 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors. May 24, 2019 538
Celgene Corporation (NASDAQ: CELG). May 22, 2019 1924
Synlogic, Roche announce collaboration to explore SYNB1891 with atezolizumab. May 22, 2019 309
Celgene Corporation (NASDAQ: CELG). May 15, 2019 1883
Pieris Pharmaceuticals reports Q1 EPS (20c), consensus (18c). Financial report May 10, 2019 186
Celgene Corporation (NASDAQ: CELG). May 9, 2019 1878
Celgene Corporation (NASDAQ: CELG). May 2, 2019 1920
Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma. Ghali, Fady; Patel, Sunil H.; Derweesh, Ithaar H. Apr 30, 2019 5953
The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. Vigliar, Elena; Malapelle, Umberto; Bono, Francesca; Fusco, Nicola; Cortinovis, Diego; Valtorta, Ema Apr 30, 2019 3972
Forty Seven expands agreement with Genentech for third 5F9 with rituximab trial. Apr 26, 2019 146
Celgene Corporation (NASDAQ: CELG). Apr 25, 2019 1700
Celgene Corporation (NASDAQ: CELG). Apr 16, 2019 1699
Celgene Corporation (NASDAQ: CELG). Apr 11, 2019 1742
I-Mab Biopharma partners with Roche for atezolizumab & TJD5 combination therapy study. Apr 11, 2019 153
I-Mab Biopharma partners with Roche for atezolizumab & TJD5 combination therapy study. Apr 11, 2019 149
Tesetaxel Brain Concentrations Exceeded Concentrations Required for Tumor Killing for Sustained Period of Time in Preclinical Testing, According to Odonate Therapeutics. Apr 4, 2019 951
Odonate Therapeutics Initiates CONTESSA TRIO Phase 2 Study of Tesetaxel. Apr 1, 2019 731
Espoir dans le traitement du cancer : l'immunotherapie. Mar 29, 2019 777
FDA Approves Genentech's Tecentriq in Combination with Chemotherapy for the Initial Treatment of Adults with Extensive-Stage Small Cell Lung Cancer. Mar 21, 2019 390
CSI Laboratories Begins offering Ventana PD-L1 (SP142) Assay as Companion Diagnostic Test for Triple Negative Breast Cancer as a Result of FDA Approval for Tencentriq. Mar 20, 2019 257
Roche's Tecentriq chemotherapy combination granted FDA approval for the initial treatment of adults with extensive-stage small cell lung cancer. Mar 19, 2019 293
Roche's Tecentriq chemotherapy combination granted FDA approval for the initial treatment of adults with extensive-stage small cell lung cancer. Mar 19, 2019 289
Celgene Provides Update on Abraxane Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer. Mar 14, 2019 668
EC approves marketing authorisation for Roche's Tecentriq in combination with Avastin and chemotherapy. Mar 12, 2019 252
EC approves marketing authorisation for Roche's Tecentriq in combination with Avastin and chemotherapy. Mar 12, 2019 248
Systemic Therapy in Metastatic Castration-Resistant Prostate Cancer/Metastatik Kastrasyona Direncli Prostat Kanserinde Sistemik Tedavi. Dulgar, Ozgecan; Yilmaz, Mesut; Tural, Deniz Nov 1, 2018 2940
Chemoimmunotherapy Ups Survival in Triple-Negative Breast Cancer; Atezolizumab plus nab-paclitaxel prolongs progression-free survival in metastatic disease. Oct 22, 2018 298
PD-L1 Expression and [CD8.sup.+] T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer. Wang, Yangyang; Zhu, Chunchao; Song, Wei; Li, Jun; Zhao, Gang; Cao, Hui Jan 1, 2018 5581
Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis. Su, Qiang; Zhang, Xiao-chen; Zhang, Chen-guang; Hou, Yan-li; Yao, Yu-xia; Cao, Bang-wei Jan 1, 2018 5793
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Sui, Hongshu; Ma, Ningxia; Wang, Ying; Li, Hui; Liu, Xiaoming; Su, Yanping; Yang, Jiali Clinical report Jan 1, 2018 12468
The Application of Nanoparticle-Based Drug Delivery Systems in Checkpoint Blockade Cancer Immunotherapy. Zhao, Huan; Li, Yuanqi; Wei, Dan; Luo, Hongrong Jan 1, 2018 6860
Combination Immunotherapy Approaches for Pancreatic Cancer Treatment. Cheng, Xianliang; Zhao, Gang; Zhao, Yunqi Jan 1, 2018 5627
A Complex Cardiac Mass Originating from Interatrial Septum in a Patient with History of Kidney Cancer: A Case Report and Literature Review. Faramarzi, Negar; Sohal, Sumit; Habibi, Roshanak; Akbar, Muhammad Sikander Jan 1, 2018 1547
A Rare Presentation of Cardiac Tamponade from Metastatic Urothelial Carcinoma of the Bladder. Palam, Sowmya; Kapoor, Ridhima; Kulinski, Jacquelyn Jan 1, 2018 1815
Transforming of the Tumor Microenvironment: Implications for TGF-[beta] Inhibition in the Context of Immune-Checkpoint Therapy. Loffek, Stefanie Jan 1, 2018 6917
Update on the Treatment of Metastatic Urothelial Carcinoma. Bukhari, Nedal; Al-Shamsi, Humaid O.; Azam, Faisal Clinical report Jan 1, 2018 5209
Precision Medicine for Breast Cancer: The Paths to Truly Individualized Diagnosis and Treatment. Harris, Eleanor E.R. Report Jan 1, 2018 6464
Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer. D'Ascanio, Michela; Pezzuto, Aldo; Fiorentino, Chiara; Sposato, Bruno; Bruno, Pierdonato; Grieco, Al Jan 1, 2018 4042
Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials. Zhao, Qiuling; Xie, Ruixiang; Lin, Shen; You, Xiang; Weng, Xiuhua Jan 1, 2018 5282

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters